What I Tell My Patients About ...

The Similarities and Differences Between Diffuse Large B-Cell Lymphoma (DLBCL) and Other Forms of Lymphoma

• Various subtypes of non-Hodgkin lymphoma; biologic and clinical characteristics of DLBCL
• Potential for cure in the treatment of DLBCL versus other subtypes of non-Hodgkin lymphoma
• Relevance of cell of origin and implications for prognosis and treatment
• Historical approaches to the management of newly diagnosed DLBCL; current role of chemoimmunotherapy

The Potential Role of Polatuzumab Vedotin as a Component of Up-Front Treatment for DLBCL

• Structural components and mechanism of antitumor activity of polatuzumab vedotin
• Published results with polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL; effectiveness of this regimen in various subgroups (eg, cell of origin, IPI score, bulk of disease)
• Tolerability of polatuzumab vedotin-based therapy in the up-front setting; comparison to the experience in relapsed disease
• Upcoming FDA review and potential role of polatuzumab vedotin as a component of up-front therapy for newly diagnosed DLBCL

The Current Role of Polatuzumab Vedotin in Therapy for Relapsed/Refractory (R/R) DLBCL

• Long-term research findings with polatuzumab vedotin in combination with bendamustine/rituximab (BR) for patients with R/R DLBCL
• Selection and sequencing of polatuzumab vedotin/BR among other evidence-based options
• Appropriate use of polatuzumab vedotin for patients with R/R disease for whom chimeric antigen receptor (CAR) T-cell therapy is planned
• Spectrum, frequency and severity of toxicities reported with polatuzumab vedotin in R/R DLBCL

The Role of Tafasitamab/Lenalidomide in DLBCL Management

• Biologic rationale for targeting CD19 in DLBCL
• Mechanism of action of tafasitamab and rationale for combining it with lenalidomide
• Published clinical trial and real-world findings with tafasitamab/lenalidomide for R/R DLBCL
• Patient selection for tafasitamab/lenalidomide and appropriate integration into treatment algorithms

Side Effects and the Practical Implementation of Tafasitamab/Lenalidomide Therapy

• Dose and schedule of tafasitamab/lenalidomide; frequency of infusion reactions and role of premedication
• Spectrum and frequency of toxicities associated with tafasitamab/lenalidomide, such as infection and myelosuppression; optimal monitoring and management approaches
• Duration of treatment with tafasitamab/lenalidomide; rationale for stopping lenalidomide but continuing tafasitamab

Loncastuximab Tesirine and Its Use in DLBCL Management

• Structural components and mechanism of action of loncastuximab tesirine
• Principal efficacy and safety findings with loncastuximab tesirine for patients with R/R DLBCL
• FDA-approved indication for and current role of loncastuximab tesirine for patients with R/R DLBCL

Tolerability and Other Practical Considerations with Loncastuximab Tesirine

• Incidence and severity of common adverse reactions, including laboratory abnormalities, observed with loncastuximab tesirine
• Frequency of myelosuppression and recommended monitoring of blood cell counts in patients receiving loncastuximab tesirine
• Pathophysiology of effusion and edema associated with loncastuximab tesirine; indications for diagnostic imaging and intervention
• Cutaneous toxicity, including photosensitivity reactions, experienced with loncastuximab tesirine; counseling patients about dermatologic consultation and limiting sun exposure

The Efficacy and Safety of CAR T-Cell Therapy in DLBCL

• Mechanism of action of CAR T-cell therapy; similarities and differences among available CAR T-cell platforms targeting CD19
• Long-term follow-up from clinical trials evaluating the efficacy and safety of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel for DLBCL that has relapsed on or after multiple lines of therapy
• Available results with CAR T-cell therapy as second-line treatment for patients with DLBCL
• Spectrum, frequency and severity of class-effect (eg, cytokine release syndrome [CRS], neurotoxicity) and other toxicities with CAR T-cell therapy

Bispecific Antibodies and Their Potential Role in Therapy for DLBCL

• Mechanism of action of CD20 x CD3 bispecific antibodies under investigation for R/R DLBCL, such as glofitamab, epcoritamab and odronextamab
• Pivotal clinical trial results with glofitamab, epcoritamab and odronextamab for patients with multiregimen-relapsed DLBCL
• Potential role of CD20 x CD3 bispecific antibodies in DLBCL management; optimal sequencing relative to other evidence-based options
• Potential practical advantages of bispecific antibodies over CAR T-cell therapy because of their “off-the-shelf” nature

Tolerability and Other Practical Considerations with CD20 x CD3 Bispecific Antibodies

• Routes of administration and dosing schedules of various CD20 x CD3 bispecific antibody platforms under investigation
• Incidence, severity and time course of CRS, neurotoxicity and other side effects with CD20 x CD3 bispecific antibodies; recommended monitoring, mitigation and management protocols
• Feasibility of administering bispecific antibodies in the community-based setting